The Lazarus Pharmaceutical LZR-H3 DriftHaze occupies an uncomfortable regulatory position in GLMZ's security product ecosystem. It is classified as a 'cognitive compliance agent' — a category that Lazarus Pharmaceutical's legal team spent considerable resources lobbying into existence. The active compound is a synthetic dissociative hallucinogen designated LZR-41S, derived from a modified phenethylamine scaffold. When inhaled or absorbed through mucosal membranes, LZR-41S produces a rapid-onset perceptual disturbance state lasting 30–60 seconds, characterized by spatial disorientation, time dilation, emotional flattening, and visual pattern hallucination. Subjects report the experience as dreamlike and non-threatening during the episode, but are effectively incapable of coordinated physical action, threat assessment, or decision-making during the window. Recovery is complete in most cases, with no residual pharmacological effect beyond a brief period of mild cognitive fog lasting 5–15 minutes post-recovery.

Lazarus markets the LZR-H3 for crowd management scenarios where the goal is to interrupt coordinated group action — protests, organized resistance, or mob behavior — without causing physical injury. The aerosol is delivered as a very fine mist capable of affecting multiple individuals in a 3-meter radius with a single discharge, and the low dosage required means a standard canister holds enough compound for eight to twelve effective deployments. The manufacturer is careful to note that the compound's effects vary significantly based on existing neurochemistry, BCI load, and pre-existing conditions, and that subjects with certain psychiatric histories may experience prolonged or intensified reactions.

The LZR-H3 exists in a legal grey zone that reflects GLMZ's increasingly permissive attitude toward chemical compliance tools in the hands of licensed security actors. Human rights organizations classify it as a form of non-consensual psychoactive administration — effectively drugging people against their will — while Lazarus and its corporate clients argue that the absence of lasting physical harm places it within the same ethical category as any other incapacitating spray.